Abiraterone Acetate Attenuates SARS-CoV-2 Replication by Interfering with the Structural Nucleocapsid Protein |
Kim, Jinsoo
(Department of Microbiology, College of Medicine, Hallym University)
Hwang, Seok Young (College of Pharmacy, Natural Products Research Institute, Seoul National University) Kim, Dongbum (Institute of Medical Science, College of Medicine, Hallym University) Kim, Minyoung (Department of Microbiology, College of Medicine, Hallym University) Baek, Kyeongbin (Department of Microbiology, College of Medicine, Hallym University) Kang, Mijeong (Department of Microbiology, College of Medicine, Hallym University) An, Seungchan (College of Pharmacy, Natural Products Research Institute, Seoul National University) Gong, Junpyo (College of Pharmacy, Natural Products Research Institute, Seoul National University) Park, Sangkyu (Department of Biochemistry, College of Natural Sciences, Chungbuk National University) Kandeel, Mahmoud (Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University) Lee, Younghee (Department of Biochemistry, College of Natural Sciences, Chungbuk National University) Noh, Minsoo (College of Pharmacy, Natural Products Research Institute, Seoul National University) Kwon, Hyung-Joo (Department of Microbiology, College of Medicine, Hallym University) |
1 | Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N. H., Nitsche, A., Muller, M. A., Drosten, C. and Pohlmann, S. (2020) SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271-280.e8. DOI |
2 | Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., Shum, D. and Kim, S. (2020) Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob. Agents Chemother. 64, e00819-20. |
3 | Yao, H., Song, Y., Chen, Y., Wu, N., Xu, J., Sun, C., Zhang, J., Weng, T., Zhang, Z., Wu, Z., Cheng, L., Shi, D., Lu, X., Lei, J., Crispin, M., Shi, Y., Li, L. and Li, S. (2020) Molecular architecture of the SARS-CoV-2 virus. Cell 183, 730-738.e13. DOI |
4 | Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., Hum, Y., Tao, Z. W., Tian, J. H., Pei, Y. Y., Yuan, M. L., Zhang, Y. L., Dai, F. H., Liu, Y., Wang, Q. M., Zheng, J. J., Xu, L., Holmes, E. C. and Zhang, Y. Z. (2020) A new coronavirus associated with human respiratory disease in China. Nature 579, 265-269. DOI |
5 | Yin, L. and Hu, Q. (2014) CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents. Nat. Rev. Urol. 11, 32-42. DOI |
6 | Kandeel, M., Yamamoto, M., Tani, H., Kobayashi, A., Gohda, J., Kawaguchi, Y., Park, B. K., Kwon, H. J., Inoue, J. I. and Alkattan, A. (2021) Discovery of new fusion inhibitor peptides against SARS-CoV-2 by targeting the spike S2 subunit. Biomol. Ther. (Seoul) 29, 282-289. DOI |
7 | Jiang, S., Hillyer, C. and Du, L. (2020) Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41, 355-359. DOI |
8 | Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K., Bates, R., Zidek, A., Potapenko, A., Bridgland, A., Meyer, C., Kohl, S. A. A., Ballard, A. J., Cowie, A., Romera-Paredes, B., Nikolov, S., Jain, R., Adler, J., Back, T., Petersen, S., Reiman, D., Clancy, E., Zielinski, M., Steinegger, M., Pacholska, M., Berghammer, T., Bodenstein, S., Silver, D., Vinyals, O., Senior, A. W., Kavukcuoglu, K., Kohli, P. and Hassabis, D. (2021) Highly accurate protein structure prediction with AlphaFold. Nature 596, 583-589. DOI |
9 | Kandeel, M., Yamamoto, M., Al-Taher, A., Watanabe, A., Oh-Hashi, K., Park, B. K., Kwon, H. J., Inoue, J. I. and Al-Nazawi, M. (2020) Small molecule inhibitors of Middle East respiratory syndrome coronavirus fusion by targeting cavities on heptad repeat trimers. Biomol. Ther. (Seoul) 28, 311-319. DOI |
10 | Kjeldsen, K., Norgaard, A. and Gheorghiade, M. (2002) Myocardial Na,K-ATPase: the molecular basis for the hemodynamic effect of digoxin therapy in congestive heart failure. Cardiovasc. Res. 55, 710-713. DOI |
11 | Liu, S., Lien, C. Z., Selvaraj, P. and Wang, T. T. (2020) Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection. bioRxiv doi: 10.1101/2020.04.29.067983 [Preprint]. DOI |
12 | Yuan, S., Chan, J. F. W., Chik, K. K. H., Chan, C. C. Y., Tsang, J. O. L., Liang, R., Cao, J., Tang, K., Chen, L. L., Wen, K., Cai, J. P., Ye, Z. W., Lu, G., Chu, H., Jin, D. Y. and Yuen, K. Y. (2020) Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system. Pharmacol. Res. 159, 104960. |
13 | Zeidler, A. and Karpinski, T. M. (2020) SARS-CoV, MERS-CoV, SARS-CoV-2 comparison of three emerging coronaviruses. Jundishapur J. Microbiol. 13, e103744. |
14 | Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D., Chen, J., Luo, Y., Guo, H., Jiang, R. D., Liu, M. Q., Chen, Y., Shen, X. R., Wang, X., Zheng, X. S., Zhao, K., Chen, Q. J., Deng, F., Liu, L. L., Yan, B., Zhan, F. X., Wang, Y. Y., Xiao, G. F. and Shi, Z. L. (2020a) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270-273. DOI |
15 | Perdikari, T. M., Murthy, A. C., Ryan, V. H., Watters, S., Naik, M. T. and Fawzi, N. L. (2020) SARS-CoV-2 nucleocapsid protein phase-separates with RNA and with human hnRNPs. EMBO J. 39, e106478. |
16 | Klemm, T., Ebert, G., Calleja, D. J., Allison, C. C., Richardson, L. W., Bernardini, J. P., Lu, B. G., Kuchel, N. W., Grohmann, C., Shibata, Y., Gan, Z. Y., Cooney, J. P., Doerflinger, M., Au, A. E., Blackmore, T. R., van der Heden van Noort, G. J., Geurink, P. P., Ovaa, H., Newman, J., Riboldi-Tunnicliffe, A., Czabotar, P. E., Mitchell, J. P., Feltham, R., Lechtenberg, B. C., Lowes, K. N., Dewson, G., Pellegrini, M., Lessene, G. and Komander, D. (2020) Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2. EMBO J. 39, e106275. DOI |
17 | Matsuyama, S., Nao, N., Shirato, K., Kawase, M., Saito, S., Takayama, I., Nagata, N., Sekizuka, T., Katoh, H., Kato, F., Sakata, M., Tahara, M., Kutsuna, S., Ohmagari, N., Kuroda, M., Suzuki, T., Kageyama, T. and Takeda, M. (2020) Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl. Acad. Sci. U.S.A. 117, 7001-7003. DOI |
18 | Padmanabhan, P., Desikan, R. and Dixit, N. M. (2020) Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection. PLoS Comput. Biol. 16, e1008461. |
19 | Park, B. K., Kim, D., Park, S., Maharjan, S., Kim, J., Choi, J. K., Akauliya, M., Lee, Y. and Kwon, H. J. (2021a) Differential signaling and virus production in Calu-3 cells and Vero cells upon SARS-CoV-infection. Biomol. Ther. (Seoul) 29, 273-281. DOI |
20 | Park, B. K., Kim, J., Park, S., Kim, D., Kim, M., Baek, K., Bae, J. Y., Park, M. S., Kim, W. K., Lee, Y. and Kwon, H. J. (2021b) MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein. Theranostics 11, 3853-3867. DOI |
21 | Cho, J., Lee, Y. J., Kim, J. H., Kim, S. I., Kim, S. S., Choi, B. S. and Choi, J. H. (2020) Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19. Sci. Rep. 10, 16200. |
22 | Zhou, R., Zeng, R., von Brunn, A. and Lei, J. (2020b) Structural characterization of the C-terminal domain of SARS-CoV-2 nucleocapsid protein. Mol. Biomed. 1, 2. |
23 | Zinzula, L., Basquin, J., Bohn, S., Beck, F., Klumpe, S., Pfeifer, G., Nagy, I., Bracher, A., Hartl, F. U. and Baumeister, W. (2020) High-resolution structure and biophysical characterization of the nucleocapsid phosphoprotein dimerization domain from the Covid-19 severe acute respiratory syndrome coronavirus 2. Biochem. Biophys. Res. Commun. 538, 54-62. |
24 | Kang, S., Yang, M., Hong, Z., Zhang, L., Huang, Z., Chen, X., He, S., Zhou, Z., Zhou, Z., Chen, Q., Yan, Y., Zhang, C., Shan, H. and Chen, S. (2020) Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharm. Sin. B 10, 1228-1238. DOI |
25 | Khailany, R. A., Safdar, M. and Ozaslan, M. (2020) Genomic characterization of a novel SARS-CoV-2. Gene Rep. 19, 100682. |
26 | Kim, D., Maharjan, S., Kim, J., Park, S., Park, J. A., Park, B. K., Lee, Y. and Kwon, H. J. (2021a) MUC1-C influences cell survival in lung adenocarcinoma Calu-3 cells after SARS-CoV-2 infection. BMB Rep. 54, 425-430. DOI |
27 | Datta, P. K., Liu, F., Fischer, T., Rappaport, J. and Qin, X. (2020) SARS-CoV-2 pandemic and research gaps: understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Theranostics 10, 7448-7464. DOI |
28 | Farag, A. B., Wang, P., Boys, I. N., Eitson, J. L., Ohlson, M. B., Fan, W., McDougal, M. B., Amed, M. S., Schoggins, J. W. and Sadek, H. A. (2020) Identification of Atovaquone, Ouabain and Mebendazole as FDA approved drugs targeting SARS-CoV-2 (Version 4). ChemRxiv doi: 10.26434/chemrxiv.12003930.v4 [Preprint]. DOI |
29 | Forli, S., Huey, R., Pique, M. E., Sanner, M. F., Goodsell, D. S. and Olson, A. J. (2016) Computational protein-ligand docking and virtual drug screening with the AutoDock suite. Nature Protoc. 11, 905-919. DOI |
30 | Riva, L., Yuan, S., Yin, X., Martin-Sancho, L., Matsunaga, N., Burgstaller-Muehlbacher, S., Pache, L., De Jesus, P. P., Hull, M. V., Chang, M., Chan, J. F., Cao, J., Poon, V. K., Herbert, K., Nguyen, T. T., Pu, Y., Nguyen, C., Rubanov, A., Martinez-Sobrido, L., Liu, W. C., Miorin, L., White, K. M., Johnson, J. R., Benner, C., Sun, R., Schultz, P. G., Su, A., Garcia-Sastre, A., Chatterjee, A. K., Yuen, K. Y. and Chanda, S. K. (2020) A large-scale drug repositioning survey for SARS-CoV-2 antivirals. bioRxiv doi: 10.1101/2020.04.16.044016 [Preprint]. DOI |
31 | Satarker, S. and Nampoothiri, M. (2020) Structural proteins in severe acute respiratory syndrome coronavirus-2. Arch. Med. Res. 51, 482-491. DOI |
32 | Sternberg, A., McKee, D. L. and Naujokat, C. (2020) Novel drugs targeting the SARS-CoV-2/COVID-19 machinery. Curr. Top. Med. Chem. 20, 1423-1433. DOI |
33 | Weston, S., Coleman, C. M., Haupt, R., Logue, J., Matthews, K., Li, Y., Reyes, H. M., Weiss, S. R. and Frieman, M. B. (2020) Broad anti-coronavirus activity of Food and Drug Administration-approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo. J. Virol. 94, e01218-20. |
34 | Park, B. K., Maharjan, S., Lee, S. I., Kim, J., Bae, J. Y., Park, M. S. and Kwon, H. J. (2019) Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex. BMB Rep. 52, 397-402. DOI |
35 | Furstenau, M., Langerbeins, P., De Silva, N., Fink, A. M., Robrecht, S., von Tresckow, J., Simon, F., Hohloch, K., Droogendijk, J., van der Klift, M., van der Spek, E., Illmer, T., Schottker, B., Fischer, K., Wendtner, C. M., Tausch, E., Stilgenbauer, S., Niemann, C. U., Gregor, M., Kater, A. P., Hallek, M. and Eichhorst, B. (2020) COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia 34, 2225-2229. DOI |
36 | Kim, J., Kim, M., Kim, D., Park, S., Kang, M., Baek, K., Choi, J. K., Maharjan, S., Akauliya, M., Lee, Y. and Kwon, H. J. (2022) Targeting the interaction between spike protein and nucleocapsid protein for suppression and detection of human coronavirus OC43. Front. Immunol. 13, 835333. |
37 | Maharjan, S., Kang, M., Kim, J., Kim, D., Park, S., Kim, M., Baek, K., Lee, Y. and Kwon, H. J. (2021) Apoptosis enhances the replication of human coronavirus OC43. Viruses 13, 2199. |
38 | Kim, D., Kim, J., Park, S., Kim, M., Baek, K., Kang, M., Choi, J. K., Maharjan, S., Akauliya, M., Lee, Y. and Kwon, H. J. (2021b) Production of SARS-CoV-2 N protein-specific monoclonal antibody and its application in an ELISA-based detection system and targeting the interaction between the spike C-terminal domain and N protein. Front. Microbiol. 12, 726231. |